Stocks
News
ETFs
Economy
Currencies
Press Releases
Articles from Innate Pharma SA
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 15, 2025
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 10, 2025
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 2, 2025
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
Regulatory news:
By
Innate Pharma SA
· Via
Business Wire
· August 4, 2025
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· July 29, 2025
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· July 4, 2025
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· June 17, 2025
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· June 13, 2025
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 27, 2025
Outcome of Innate Pharma’s 2025 Annual General Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 23, 2025
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 23, 2025
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 19, 2025
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 15, 2025
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 13, 2025
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 12, 2025
Innate Pharma announces conference call and webcast for Q1 2025 business update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 6, 2025
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 30, 2025
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 29, 2025
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 28, 2025
Innate Pharma Announces €15M Investment by Sanofi
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 24, 2025
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 23, 2025
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 3, 2025
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 27, 2025
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 26, 2025
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 25, 2025
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 20, 2025
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 27, 2025
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 17, 2025
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 27, 2025
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 21, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 16, 2025
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 10, 2025
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 20, 2024
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 9, 2024
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 6, 2024
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 3, 2024
Innate Pharma Releases Its 2025 Financial Calendar
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· November 20, 2024
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· November 19, 2024
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· November 13, 2024
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· November 8, 2024
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· November 7, 2024
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· October 29, 2024
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· October 14, 2024
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 30, 2024
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 23, 2024
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 12, 2024
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 9, 2024
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 5, 2024
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· September 4, 2024
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· July 25, 2024
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· June 18, 2024
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· June 17, 2024
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· June 4, 2024
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 28, 2024
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 24, 2024
Outcome of Innate Pharma’s 2024 Annual General Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 23, 2024
Innate Pharma: Clarification Regarding SAR443579 Designation
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 21, 2024
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 15, 2024
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 14, 2024
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 7, 2024
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 15, 2024
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 15, 2024
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 10, 2024
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 9, 2024
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 5, 2024
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 21, 2024
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 19, 2024
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 14, 2024
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 6, 2024
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 6, 2024
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 21, 2024
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 4, 2024
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 4, 2024
